Table 3.

Probabilities of acute and chronic GVHD, nonrelapse mortality, relapse, and OS by donor type

	Donor type
Outcome	Haploidentical	Unrelated	P
Myeloablative transplants
Grade 2-4 acute GVHD at day 90	16% (10-24)	33% (30-35)	<.0001
Grade 3-4 acute GVHD at day 90	7% (3-13)	13% (11-15)	.02
Chronic GVHD
At 12 mo	28% (20-37)	45% (42-47)	.0005
At 36 mo	30% (21-39)	53% (50-56)	<.0001
Nonrelapse mortality
At 12 mo	12% (7-19)	14% (12-16)	.56
At 36 mo	14% (8-22)	20% (18-22)	.14
Relapse
At 12 mo	41% (33-50)	32% (30-35)	.04
At 36 mo	44% (34-53)	39% (37-42)	.37
OS
At 12 mo	65% (56-73)	65% (63-68)	.98
At 36 mo	45% (36-54)	50% (47-53)	.38
Reduced intensity transplants
Grade 2-4 acute GVHD at day 90	19% (12-28)	28% (25-31)	.05
Grade 3-4 acute GVHD at day 90	2% (0-7)	11% (8-13)	<.0001
Chronic GVHD
At 12 mo	27% (19-37)	43% (40-47)	.001
At 36 mo	34% (24-44)	52% (48-55)	.002
Nonrelapse mortality
At 12 mo	6% (2-12)	16% (13-18)	.0001
At 36 mo	9% (4-16)	23% (19-26)	.0001
Relapse
At 12 mo	43% (32-53)	34% (31-38)	.12
At 36 mo	58% (46-68)	42% (38-45)	.006
OS
At 12 mo	64% (53-73)	60% (56-63)	.46
At 36 mo	46% (35-56)	44% (40-47)	.71